Results 51 to 60 of about 24,787 (310)

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion, Peta‐Lee Sacks, Lu Hui Png, Ruoxin Hua, Rhea Darbari Kaul, Raquel Alvarado, Christine Choy, Raymond Sacks, Peter Earls, Raewyn G. Campbell, Larry Kalish, Richard J. Harvey   +11 more
wiley   +1 more source

Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis [PDF]

, 2019
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation.
Castro, Mario, et al,, Maspero, Jorge F
core   +1 more source

Molecular mechanisms in atopic eczema:insight gained from genetic studies [PDF]

, 2017
Atopic eczema (synonymous with atopic dermatitis and eczema) is a common heterogeneous phenotype with a wide spectrum of severity from mild transient disease to a severe chronic disorder with atopic and non-atopic co-morbidities.
Adoue, Barrett, Baurecht, Beck, Bieber, Boguniewicz, Broussard, Brown, Brown, Brown, Brown, Brown, Brown, Brown, Caubet, Cole, Deckert, Esaki, Esparza-Gordillo, Eyerich, Gao, Ghosh, He, He, Henderson, Horimukai, Hotze, Howell, Hubiche, Irvine, Johansson, Kelleher, Kelleher, Kim, Liu, Margolis, Margolis, McAleer, Noda, Odhiambo, Paller, Paller, Palmer, Paternoster, Rodriguez, Samuelov, Sandilands, Schmitt, Schmitt, Silverberg, Simpson, Smith, Strom, Suarez-Farinas, Takai, Tang, Taylan, Thaci, Tsianakas, Walley, Weidinger, Weidinger, Williams, Williams, Zhang   +64 more
core   +2 more sources

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases [PDF]

, 2021
Jennifer D. Hamilton, Sivan Harel, Brian N. Swanson, William R. Brian, Zhen Chen, Megan S. Rice, Nikhil Amin, Marius Ardeleanu, Allen Radin, Brad Shumel, Marcella Ruddy, Naimish Patel, Gianluca Pirozzi, Leda Mannent, Neil M.H. Graham   +14 more
openalex   +1 more source

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Conjunctivitis in patients with atopic dermatitis treated with dupilumab

Drugs in Context, 2020
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL- 13 are key cytokines in the immunopathogenesis of AD.
Sandra Ferreira, Tiago Torres
doaj   +1 more source

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

Frontiers in Immunology, 2021
BackgroundBullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed.
Yihua Zhang, Qiuyun Xu, Lihong Chen, Jiawen Chen, Jing Zhang, Ying Zou, Ting Gong, Chao Ji   +7 more
doaj   +1 more source

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis

Clinical Pharmacology &Therapeutics, EarlyView.
Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617)
Jenny‐Hoa Nguyen, Mirna Chehade, Evan S. Dellon, Allen Radin, Jason Chittenden, Mohamed A. Kamal, Margee Louisias, Christine Xu, Matthew P. Kosloski   +8 more
wiley   +1 more source

Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment

Journal of Dermatological Treatment
Background Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.Objectives To compare ocular outcomes and conjunctival
Paulina Stepinska, Kamila Zawadzinska-Halat, Maciej Pastuszczak   +2 more
doaj   +1 more source

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. [PDF]

, 2019
BackgroundComparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited.
Apfelbacher, CJ, Arents, BWM, Barbarot, S, Bosma, AL, Deleuran, M, Eichenfield, LF, Flohr, C, Gerbens, LAA, International TREAT Registry Taskforce, Irvine, AD, Manca, A, Middelkamp-Hup, MA, Schmitt, J, Spuls, PI, Vermeulen, FM, Vestergaard, C, Wall, D, Weidinger, S   +17 more
core